A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 270-275

  Kim, Se Hyun ^a   Shim, Hyo Sup ^b   Cho, Jaeho ^a   Jeong, Jae Heon ^c   Kim, Sun Mi ^b   Hong, Yun Kyoung ^d   Sung, Ji Hee ^d   Ha, Sang Jun ^e   Kim, Hye Ryun ^a   Chang, Hyun ^a   Kim, Joo Hang ^a   Tania, Crombet ^f   Cho, Byoung Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d JE UK Institute for Cancer Research   (South Korea)

^e Yonsei University   (South Korea)

^f CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

EGFR; Gefitinib; Nimotuzumab; NSCLC; Phase I

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; K RAS PROTEIN; NIMOTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXON; FATIGUE; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; METASTASIS; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SKIN TOXICITY; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84873185233     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.11.017     Document Type: Article

References (40)

1. Youlden D.R., Cramb S.M., Baade P.D. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3:819-831.
2. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
3. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
4. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
5. Pavelic K., Banjac Z., Pavelic J., Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993, 13:1133-1137.
6. Fujino S., Enokibori T., Tezuka N., Asada Y., Inoue S., Kato H., et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996, 32A:2070-2074.
7. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
8. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
9. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
10. Mok T.S., Wu Y., Thongprasert S., Yang C., Chu D., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
11. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Janne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
12. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
13. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
14. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105:2070-2075.
15. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
16. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004, 64:5355-5362.
17. Matar P., Rojo F., Cassia R., Moreno-Bueno G., Di Cosimo S., Tabernero J., et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004, 10:6487-6501.
18. Regales L., Gong Y., Shen R., de Stanchina E., Vivanco I., Goel A., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009, 119:3000-3010.
19. Janjigian Y.Y., Azzoli C.G., Krug L.M., Pereira L.K., Rizvi N.A., Pietanza M.C., et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011, 17:2521-2527.
20. Boland W.K., Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009, 9:1199-1206.
21. Rodriguez M.O., Rivero T.C., del Castillo Bahi R., Muchuli C.R., Bilbao M.A., Vinageras E.N., et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010, 9:343-349.
22. Massimino M., Bode U., Biassoni V., Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 2011, 11:247-256.
23. Krishnamurthyreddy B., Vidyasagar M.S., Koteshwar R., Shenoy A., Viswanath L., Thimmaiah N., et al. A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. J Clin Oncol 2009, 15s.
24. Rojo F., Gracias E., Villena N., Cruz T., Corominas J.M., Corradino I., et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 2010, 16:2474-2482.
25. Crombet T., Osorio M., Cruz T., Roca C., del Castillo R., Mon R., et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22:1646-1654.
26. Bebb G., Smith C., Rorke S., Boland W., Nicacio L., Sukhoo R., et al. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2011, 67:837-845.
27. Choi H.J., Sohn J.H., Lee C.G., Shim H.S., Lee I.J., Yang W.I., et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 2011, 71:55-59.
28. You B., Brade A., Magalhaes J.M., Siu L.L., Oza A., Lovell S., et al. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 2011, 29:996-1003.
29. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
30. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
31. Riely G.J., Kris M.G., Rosenbaum D., Marks J., Li A., Chitale D.A., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14:5731-5734.
32. Cho B.C., Im C.K., Park M.S., Kim S.K., Chang J., Park J.P., et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007, 25:2528-2533.
33. Pirker R., Pereira J.R., von Pawel J., Krzakowski M., Ramlau R., Park K., et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2011, 13:33-42.
34. Boland W., Bebb G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics 2010, 4:289-298.
35. Janjigian Y., Groen H., Horn L., Smit E., Yali Fu F., Shahidi M. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011, 29:7525. (Meeting abstracts).
36. Wu J.Y., Wu S.G., Yang C.H., Gow C.H., Chang Y.L., Yu C.J., et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008, 14:4877-4882.
37. Yasuda H., Kobayashi S., Costa D.B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2011.
38. Garrido G., Rabasa A., Gracia E., Tikhomirov I., Crombet-Ramos T., Viloria-Petit A. Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit its interaction with the EGFR in renal and epidermal cells. AACR annual meeting proceedings 2009, (abstract 2763).
39. Talavera A., Friemann R., Gomez-Puerta S., Martinez-Fleites C., Garrido G., Rabasa A., et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009, 69:5851-5859.
40. Crombet T., Torres L., Neninger E., Catala M., Solano M.E., Perera A., et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003, 26:139-148.